EUVIMEDEUVIMED entdecken
Crossref

Astaxanthin protects against pirarubicin-induced H9c2 cardiomyocytes by adjusting microRNA-494-3p-mediated MDM4/p53 signalling pathway

Peng Huang, Yibing Zhang, Fengjun Wang, Meng Qin, Jiulong Ma, Jiahua Ji, Dexian Wei, Liqun Ren iD

Journal of Pharmacy and Pharmacology · 2023

DOI: 10.1093/jpp/rgad084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2023. Verfasst von Peng Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Pharmacology and Toxicology, School of Pharmacy, Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, MicroRNAs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Pirarubicin (THP) is an antitumour drug widely used in clinical practice, but its cardiotoxicity limits its application. THP cardiotoxicity must be treated as soon as possible. There is an urgent need to find drugs that alleviate THP cardiotoxicity. The purpose of this study was to investigate the effects and mechanisms of Astaxanthin (AST) on THP-induced cardiomyocytes.

Methods

Rat cardiomyocytes H9c2 were induced with THP. The effects of AST on THP-induced H9c2 and its mechanism were investigated by CCK8, reactive oxygen species assay, tunnel assay, flow cytometry, RT-qPCR, and Western blot.

Results

AST increased cell viability, inhibited apoptosis and accelerated cell cycle progression, reduced oxidative damage and inflammatory response in THP-induced H9c2; down-regulated miR-494-3p expression, promoted MDM4 expression, inhibited p53 activation, and suppressed apoptosis-related protein expression. Overexpression of MiR-494-3p reversed the above effects of AST.

Conclusions

AST can inhibit H9c2 apoptosis induced by THP and attenuate H9c2 damage by THP, which may be achieved by downregulating miR-494-3p, upregulating MDM4, and inhibiting p53.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53MicroRNAsRatsAnimalsCell LineMyocytes, CardiacCardiotoxicityApoptosisDoxorubicinXanthophylls

Stichwörter der Autor:innen

H9c2astaxanthinmiR-494-3pmiR-494-3p/MDM4/p53pirubicin

Substanzen

Tumor Suppressor Protein p53MicroRNAspirarubicinDoxorubicinastaxanthineXanthophyllsMIRN494 microRNA, rat

Autor:innen und Institutionen

  • Department of Experimental Pharmacology and Toxicology, School of Pharmacy, Jilin University, Changchun, China.
  • Department of Ophthalmology, The First Hospital of Jilin University, Changchun, China.
  • Department of Hepatobiliary Surgery, Songyuan Central Hospital, Songyuan, China.

ORCID-Profile: Liqun Ren

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, P., Zhang, Y., Wang, F., Qin, M., Ma, J., Ji, J., Wei, D., & Ren, L. (2023). Astaxanthin protects against pirarubicin-induced H9c2 cardiomyocytes by adjusting microRNA-494-3p-mediated MDM4/p53 signalling pathway. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad084

Vancouver

Huang P, Zhang Y, Wang F, Qin M, Ma J, Ji J, et al. Astaxanthin protects against pirarubicin-induced H9c2 cardiomyocytes by adjusting microRNA-494-3p-mediated MDM4/p53 signalling pathway. Journal of Pharmacy and Pharmacology. 2023. doi:10.1093/jpp/rgad084

BibTeX
@article{Huang2023,
  author = {Huang, Peng and Zhang, Yibing and Wang, Fengjun and Qin, Meng and Ma, Jiulong and Ji, Jiahua and Wei, Dexian and Ren, Liqun},
  title = {Astaxanthin protects against pirarubicin-induced H9c2 cardiomyocytes by adjusting microRNA-494-3p-mediated MDM4/p53 signalling pathway},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2023},
  doi = {10.1093/jpp/rgad084}
}
Kostenlos starten →